Metabolomic changes in autopsy-confirmed Alzheimer's disease

被引：124

作者：

Kaddurah-Daouk, Rima ^{[1
]}

Rozen, Steve ^{[1
,2
]}

Matson, Wayne ^{[3
]}

Han, Xianlin ^{[4
]}

Hulette, Christine M. ^{[5
,6
]}

Burke, James R. ^{[5
]}

Doraiswamy, P. Murali ^{[1
]}

Welsh-Bohmer, Kathleen A. ^{[1
,5
]}

机构：

[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA

[2] Duke NUS Grad Med Sch, Dept Med, Singapore, Singapore

[3] Bedford VA Med Ctr, Dept Syst Biochem, Bedford, MA USA

[4] Washington Univ, Dept Med, St Louis, MO USA

[5] Duke Univ, Dept Psychiat, Joseph & Kathleen Bryan Alzheimer Dis Res Ctr, Durham, NC 27706 USA

[6] Duke Univ, Dept Pathol, Durham, NC 27706 USA

来源：

ALZHEIMERS & DEMENTIA | 2011年 / 7卷 / 03期

关键词：

Metabolomics; Alzheimer's; Biomarkers; Diagnosis; Staging; Tryptophan; Tyrosine; Purine; GLOBAL BIOCHEMICAL APPROACH; NOREPINEPHRINE; BIOMARKERS; DIAGNOSIS; DEMENTIA; MODELS;

D O I：

10.1016/j.jalz.2010.06.001

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Metabolomics, the global science of biochemistry, provides powerful tools to map perturbations in the metabolic network and enables simultaneous quantification of several metabolites to identify metabolic perturbances that might provide insights into disease. Methods: In this pilot study, we took a targeted electrochemistry-based metabolomics approach where liquid chromatography followed by coulometric array detection enables quantification of over 30 metabolites within key neurotransmitter pathways (dopamine and serotonin) and pathways involved in oxidative stress. Results: Using samples from postmortem ventricular cerebrospinal fluid (15 Alzheimer's disease [AD] and 15 nondemented subjects with autopsy-confirmed diagnoses) and by using regression models, correlations, Wilcoxon rank-sum tests, and t-tests we identified alterations in tyrosine, tryptophan, purine, and tocopherol pathways in patients with AD. Reductions in norepinephrine and its related metabolites were also seen, consistent with previously published data. Conclusions: These data support further investigation of metabolomics in larger samples of clinical AD as well as in those with preclinical disease for use as biomarkers. (C) 2011 The Alzheimer's Association. All rights reserved.

引用

页码：309 / 317

页数：9

共 41 条

[1] CHANGES IN THE BRAIN CATECHOLAMINES IN PATIENTS WITH DEMENTIA OF ALZHEIMER TYPE [J].